- AtriCure press release (NASDAQ:ATRC): Q1 Non-GAAP EPS of -$0.23 beats by $0.12.
- Revenue of $93.5M (+25.4% Y/Y) beats by $5.97M.
- 2023 Financial Guidance
- Full year 2023 revenue is projected to be $385 million to $392 million vs $382.60M consensus, reflecting growth of approximately 17% to 19% over full year 2022. Management now expects full year 2023 positive adjusted EBITDA of approximately $2 million, and full year 2023 adjusted loss per share of approximately $1.10 to $1.15 vs -$1.13 consensus.
AtriCure Non-GAAP EPS of -$0.23 beats by $0.12, revenue of $93.5M beats by $5.97M
Recommended For You
More Trending News
About ATRC Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ATRC | - | - |
AtriCure, Inc. |